| Name | Title | Contact Details |
|---|
Cancer. Diabetes. Alzheimer`s. Heart Disease. Parkinson`s. The Jackson Laboratory (JAX) leads the search to cure diseases rooted in our DNA. We are an NCI-designated Cancer Center since 1983 and an independent 501(c)3 nonprofit organization with over 85 years of experience in genetics and genomics research. JAX blends the brightest minds with state-of-the-art resources to accelerate discovery. Areas of Discovery (65+ Principal Investigators, >250 Ph.D.s, M.D.s, and D.V.M.s): • Cancer: We are a National Cancer Institute designated Cancer Center focusing on cancer initiation, progression, prevention and therapies. • Developmental/reproductive biology: birth defects, Down syndrome, osteoporosis, fertility • Immunology: HIV-AIDS, anemia, autoimmunity, cancer immunology, immune disorders, lupus, transplant rejection • Metabolic diseases: atherosclerosis, cardiovascular disease, diabetes, high blood pressure, obesity, microbiome • Neurobiology: blindness, Parkinson`s, Alzheimer`s, deafness, epilepsy, glaucoma, macular degeneration, neurodegenerative diseases • Neurobehavioral disorders: autism, addiction, depression Supporting Global Research: • The JAX Mouse Repository and Scientific Services are among the premier resources available for biomedical research. • 2.5 million JAX® Mice are distributed annually to more than 900 institutions in 56 countries. Committed to Education: • Summer Student Program (undergrad & high school) • Teaching the Genome Generation Short Course • Ph.D. programs: U. Maine, Tufts University and U. Connecticut • Courses, Conferences and Workshops
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free.
PVLSI - Pioneer Valley Life Sciences Institute is a Springfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MidMark is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pathology Services Inc is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.